| 000 | 01800 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250516062705.0 | ||
| 264 | 0 | _c20120326 | |
| 008 | 201203s 0 0 eng d | ||
| 022 | _a1932-6203 | ||
| 024 | 7 |
_a10.1371/journal.pone.0026549 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWestmark, Cara J | |
| 245 | 0 | 0 |
_aReversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice. _h[electronic resource] |
| 260 |
_bPloS one _c2011 |
||
| 300 |
_ae26549 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAmyloid beta-Peptides _xblood |
| 650 | 0 | 4 |
_aAmyloid beta-Protein Precursor _xblood |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBrain Chemistry |
| 650 | 0 | 4 | _aDendritic Spines |
| 650 | 0 | 4 | _aDown-Regulation |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFragile X Mental Retardation Protein _xgenetics |
| 650 | 0 | 4 |
_aFragile X Syndrome _xgenetics |
| 650 | 0 | 4 | _aGenetic Therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Knockout |
| 650 | 0 | 4 |
_aNeurons _xultrastructure |
| 650 | 0 | 4 |
_aPeptide Fragments _xblood |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aReceptors, Metabotropic Glutamate _xgenetics |
| 700 | 1 | _aWestmark, Pamela R | |
| 700 | 1 | _aO'Riordan, Kenneth J | |
| 700 | 1 | _aRay, Brian C | |
| 700 | 1 | _aHervey, Crystal M | |
| 700 | 1 | _aSalamat, M Shahriar | |
| 700 | 1 | _aAbozeid, Sara H | |
| 700 | 1 | _aStein, Kelsey M | |
| 700 | 1 | _aStodola, Levi A | |
| 700 | 1 | _aTranfaglia, Michael | |
| 700 | 1 | _aBurger, Corinna | |
| 700 | 1 | _aBerry-Kravis, Elizabeth M | |
| 700 | 1 | _aMalter, James S | |
| 773 | 0 |
_tPloS one _gvol. 6 _gno. 10 _gp. e26549 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1371/journal.pone.0026549 _zAvailable from publisher's website |
| 999 |
_c21276682 _d21276682 |
||